The effect of streptolysin S on T and B human and mouse lymphocytes was studied. The dose-dependent inhibition of T cell rosette formation was observed, and this was accompanied by a dose-dependent cytotoxicity. The existence of a difference in the degree of susceptibility of T and B cells to the cytotoxic effect of streptolysin S is shown.
Streptolysin S (SLS) is a nonantigenic, cytotoxic, extracellular product elaborated by most group A streptococci. It is produced intracellularly and is subsequently released from the bacterial cell by nonspecific substances such as ribonucleic acid, human albumin, Tween, Triton, etc., which serve as carriers for the hemolytic moiety (3, 8) . It exhibits strong hemolytic activity toward erythrocytes of various origins (8) , acting on their membrane; however, unlike streptolysin 0, it produces no functional holes that can be seen by electron microscopy (6) . Recently, it was shown that erythrocyte lysis produced by SLS is an osmotic process (7) and can be inhibited by sucrose and dimethyl sulfoxide (W. Hryniewicz, S. Szmigielski, and M. Janiak, Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig. Reihe A, in press). The cytotoxic effect of SLS was also reported for leukocytes, platelets, and different cells lines (9) . The fact that SLS is non-immunogenic and cytotoxic for a wide variety of animal cells prompted us to study its influence on lymphocytes of human and animal origin. This investigation demonstrates the inhibitory effect of SLS on T lymphocyte rosette formation and the existence of a difference in susceptibility of T and B cells to cytotoxic action of this toxin.
MATERIALS AND METHODS SLS preparation. Ribonucleic acid core (Sigma Chemical Co.) SLS was prepared from streptococcal group A C203 S strain as described by Bernheimer (2) . The final product was freeze-dried (referred to as partially purified toxin) or was subjected to further purification by diethylaminoethyl-cellulose column chromatography with KCl gradient elution (0.4 to 1.0 M). The fractions with hemolytic activity but no deoxyribonuclease activity were pooled and subjected again to chromatography under the same conditions. The resulting fractions with hemolytic activity were pooled, dialyzed, and freeze-dried, followed by application to a Sephadex 75 column equilibrated with 1 M KCl in 0.1 M phosphate buffer (pH 7.0). The fractions with the highest hemolytic activity were collected and freeze-dried (referred to as highly purified toxin).
Measurement of hemolysis by SLS. The hemolytic activity was measured essentially by the method of Symington and Arbuthnott (20) , using 0.8% human group 0 erythrocytes. Instead of saponin, 0.1% sodium carbonate was used to produce complete lysis. One hemolytic unit is defined as the amount of SLS in 1 ml of sample able to produce 50% hemolysis of an equal volume of erythrocyte suspension during incubation for 30 min at 37°C. Released hemoglobin was measured spectrophotometrically at 545 nm.
Assay for deoxyribonuclease activity. Deoxyribonuclease activity was measured by the deoxyribonucleic acid-methyl green agar plate technique as described by Marker and Gray (14) .
Cell suspensions. Human lymphocytes obtained from peripheral blood of healthy donors were purified by using a Ficoll-Isopaque gradient according to B6yum (5) and were subsequently washed three times with Dulbecco balanced salt solution without calcium (BSS).
B cells (derived from bone marrow) and T cells (derived from thymus) were obtained from strain C3H/He and treated similarly to human lymphocytes.
Incubation of lymphocytes with SLS. The lymphocyte cell suspension (final concentration, 2 x 106 cells per ml) was incubated in a water bath at 37°C for 30 min with various concentrations of SLS diluted in BSS. After incubation for various time intervals, trypan blue (serving as an SLS inhibitor) was added to a final concentration of 20 ,ug/ml to inactivate the toxin (8) .
Rosette tests. T rosettes were determined as described by Jondall et al. (12) , and "active" T cell rosettes were determined by the method of Smith et al. (19) , using sheep erythrocytes (SRBC).
The B cell rosettes for separation experiments were induced by mixing lymphocytes with SRBC coated with rabbit immunoglobulin M antibodies and mouse complement by the method of Bianco et al. (4) . Rosetting and nonrosetting lymphocytes were separated by the method of Parish and Kirov (16) .
Cell viability. Viability was estimated by standard trypan blue exclusion tests, with a final concentration of dye of 0.2%.
RESULTS
Formation of T cell rosettes by human lymphocytes preincubated with various concentration of SLS. Equal volumes (0.1 ml each) of cell suspension (4 x 106 lymphocytes per ml) and various SLS concentrations were incubated at 37°C for 30 min. After the incubation, SRBC (20 ,1u of 5% SRBC) were added, and rosette formation was measured by the method of Jondall et al. (12; Table 1 ). Trypan blue was added (final concentration, 20 ug/ml) either before or after incubation.
The dose-dependent inhibition of T cell rosette formation was observed. The activity of SLS was effectively abolished in the presence of trypan blue. The control procedure consisted of untreated lymphocytes being incubated either in the presence or in the absence of trypan blue under similar conditions. This compound did not affect T rosette formation (Table 1) .
A similar experiment was carried out using as an indicator the formation of so-called "active" T cell rosettes. This was done as described for the previous experiment, but the rosetting procedure was by the method of Smith et al. (19) . The same pattern of inhibition was observed (Table 2) .
These results prompted us to question whether the observed inhibition ofT cell rosette formation was due to cytotoxic action of SLS. To resolve this problem, we decided to estimate simultaneously the number of T cell rosettes and the percentage of viable lymphocytes. Lymphocyte viability was estimated by adding trypan blue (final concentration, 0.2%) at the time of rosette counting. Both partially and highly purified SLS were included in the experiment (Fig. 1) .
Inhibition of T cell rosette formation appeared to be accompanied by dose-dependent cytotoxicity. Both T rosette inhibition and cytotoxicity curves are comparable, but T cell rosette inhibition is more pronounced.
Cytotoxic effect of SLS on human T and B lymphocyte populations. To determine whether both T and B cells are susceptible to the cytotoxic effects of SLS, we incubated peripheral lymphocytes with mouse complement (4) to form B cell rosettes. This suspension was subsequently layered on a Ficoll-Isopaque gra- dient to separate rosetting and nonrosetting lymphocytes (16) . Such cell populations were subjected to hypotonic shock to remove erythrocytes, washed, and then treated with SLS. The upper layer of cells recovered from the gradient contained 85% of the lymphocyte-forming rosettes with SRBC. The percentage of B rosettes in the pellet was 74%. The viability estimation in BSS was done by the trypan blue exclusion test (Table 3) . T-cell-enriched populations of lymphocytes were much more susceptible to SLS than B-cell-enriched populations, suggesting that SLS is preferentially cytotoxic for T lymphocytes.
Cytotoxicity of SLS to mouse T and B lymphocytes. T cells, derived from the thymus, and B cells, obtained from bone marrow, were incubated with partially and highly purified SLS, and subsequently the viability of cells was estimated by the trypan exclusion test. Preferential killing of mouse T cell populations was observed (Table 4) . A similar pattern was observed for human and mouse lymphocytes. The viable cells possessed the typical morphology, whereas damaged cells were usually enlarged.
The ribonucleic acid core used for SLS preparation was introduced as a control to all experiments exhibiting no biological action toward lymphocytes.
VOL. 16, 1977 on DISCUSSION SLS is one of the most potent hemolytic agents exerting a cytotoxic effect on a variety of animal cells. It was implicated in the pathogenesis of nonpurulent streptococcal group A sequelae such as rheumatic fever and glomerulonephritis (13) .
Surprisingly, the action of SLS on lymphocyte populations that are responsible for the specific defense mechanisms had not yet been examined except for some studies on its mitogenic activities (11) , which were later shown to be due to contaminating substances rather than to the toxin itself (17, 21) .
Our data indicate that lymphocytes are susceptible to the cytotoxic action of SLS. T cells appear to be preferentially killed, despite the origin of the lymphocytes (humans or mice). Mouse bone marrow cells were much more resistant than cells obtained from the thymus. The number of human lymphocytes forming nonimmune rosettes with SRBC was substantially reduced after treatment of lymphocytes with SLS, and a lower concentration was required than that needed to obtain comparable loss of viability (Fig. 1) .
However, it cannot be excluded that the inhibition of T cell rosette formation is a more sensitive test to assess SLS cytotoxicity than are viability studies: 90 hemolytic units per ml completely block T cell rosette formation (Tables 1 and 2), whereas 142.5 hemolytic units per ml still leave about 25% viable T cells ( The cytotoxic effect reported in this study was not related to contamination with streptococcal nucleases since highly purified and nuclease-free SLS was as active as the partially purified toxin, and nucleases recovered during the purification procedure were inactive (un- published data). The action of SLS was also different from streptolysin 0, which in our hands possessed the same activity against both lymphocyte populations, which is in keeping with findings of Andersen and Cone (1) . The mechanism of the greater susceptibility of T lymphocytes to the cytotoxicity of SLS is obscure. Hirsch et al. (10) have hypothesized that the cytotoxic effect of SLS towards leukocytes may be due to autolysis after labilization of lysosomal membranes. A possibility also exists that the observed differences are related to the surface composition of both lymphocyte populations or to reported differences in enzymatic activity (15, 19) .
